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Amaç: Ciddi konjenital nötropenisi (CKN) olan hastalar ve nötropenik 
olmayan ebeveynlerindeki granülositik ve granülositik olmayan kan 
hücrelerini incelemektir. 
Gereç ve Yöntemler: CKN’si olan 15 çocuk ve nötropenik olmayan 
21 ebeveynin lenfosit, granülosit ve monositlerinde CD95, CD95 
ligand, annexin V, hücre siklusu (periferik lenfositler, granülosiler +/- 
monositlerde) ve lenfosit alt grupları akım sitometri ile, b) hızlı hücre 
yaşlanması (lökositlerde) yaşlanma-ilişkili β-galaktozidaz boyası SA-
β-galaktosidaz boyası ile, c) agregasyon testleri agregometre ile, d) in 
vitro kanama zamanı, PFA-100 aleti ile, e) trombositlerde mepakrin 
işaretli kaba granül sayısı floresan mikroskopu ile, f) hematomorfoloji 
ışık ve elektron mikroskopu ile değerlendirildi. Hastalarda ve bazı 
ebeveynlerde CKN ile ilişkili olarak HAX1, ELANE, G6PC3, CSF3R, 
JAGN1 mutasyonları çalışıldı. 
Objective: To examine granulocytic and non-granulocytic cells in 
children with severe congenital neutropenia (SCN) and their non-
neutropenic parents. 
Materials and Methods: Fifteen patients with SCN and 21 non-
neutropenic parents were evaluated for a) CD95, CD95 ligand, annexin 
V, propidium iodide, cell cycle, and lymphocyte subsets by flow 
cytometry; b) rapid cell senescence (of leukocytes) by senescence-
associated β-galactosidase stain; c) aggregation tests by aggregometer; 
d) in vitro bleeding time by PFA-100 instrument; e) mepacrine-labeled 
dense granule number of thrombocytes by fluorescence microscope; 
and f) hematomorphology by light and electron microscope. HAX1, 
ELANE, G6PC3, CSF3R, and JAGN1 mutations associated with SCN 
were studied in patients and several parents. 
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Introduction
Severe congenital neutropenia (SCN) is a heterogeneous bone 
marrow failure syndrome characterized by recurrent infections, 
low absolute neutrophil count (<0.5x109/L), and maturation 
arrest at the promyelocyte/myelocyte stage of myelopoiesis in 
the vast majority of cases and it is due to various genetic defects 
[1,2,3]. Regular variations [4], giving rise to transient elevations 
of neutrophil counts to even >1.5x109/L with ‘intermittent 
maturation arrest’ [5], can be encountered.
Apoptosis in neutrophilic precursors plays a major role in the 
pathogenesis of SCN [1,2,6]. Reports regarding lymphocyte 
apoptosis in addition to granulocyte apoptosis have been 
restricted to a few cases [7,8], and apoptosis in monocytes has not 
been studied. Reports pertaining to non-granulocytic blood cell 
lines in SCN and patients’ non-neutropenic family members are 
also too limited [3,7,8,9,10] to make a general characterization 
of the phenotype of SCN cases with heterogeneous genetic 
backgrounds. 
We have hypothesized that, in SCN, development of all cell 
lines other than the granulocytic lineage is also impaired and 
patients’ non-neutropenic parents also carry some hematologic 
abnormalities. Our specific aim in this study is to examine the 
lymphocytes, monocytes, and granulocytes of patients with 
SCN and their family members in terms of morphology and cell 
death parameters [apoptosis and rapid cell senescence (RCS)] 
and additionally to evaluate thrombocyte morphology and 
functions and percentage of lymphocyte subsets. 
Materials and Methods
Study Participants
Severe congenital neutropenia was defined as persistent 
neutropenia (neutrophil counts of <0.5x109/L) confirmed from 
two samples a week for 6 weeks and the onset of neutropenia or 
infections early in life and deficiency in late maturation stages 
of neutrophils in bone marrow (mature neutrophils being <10%: 
central neutropenia) [4]. However, subjects whose neutrophils 
showed some spontaneous variations between <0.5x109/L 
and 1.5x109/L were not excluded [4]. Those with syndromic 
neutropenia were excluded. 
Fifteen children with SCN [age: 9.35±4.54 years; range: 1.5-
22; 8 female (F), 7 male (M)] and 21 non-neutropenic family 
members (10 mothers, 11 fathers; age: 35.14±8.92 years; range: 
23-55) were included in the study. A 22-year-old female was 
included since she had been followed in Pediatrics for 8 years.
Patients were prescribed G-CSF (5-25 µg/kg/day), 2-7 times 
weekly; however, many patients received therapy irregularly for 
economic and social reasons. Blood was drawn during periods 
in which patients had stopped therapy and patients and family 
members had not consumed any other drugs for at least 10 days 
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Results: Significant increase in apoptosis and secondary necrosis 
in monocytes, lymphocytes, and granulocytes of the patients and 
parents was detected, irrespective of the mutation type. CD95 
and CD95 ligand results implied that apoptosis was non-CD95-
mediated. Leukocytes of 25%, 12.5%, and 0% of patients, parents, 
and controls showed rapid cell senescence. The cell cycle analysis 
testable in four cases showed G1 arrest and apoptosis in lymphocytes 
of three. The patients had HAX1 (n=6), ELANE (n=2), G6PC3 (n=2), 
and unidentified (n=5) mutations. The CD3, CD4, and NK lymphocytes 
were below normal levels in 16.6%, 8.3%, and 36.4% of the patients 
and in 0%, 0%, and 15.4% of the parents (controls: 0%, 0%, 5.6%). 
The thrombocytes aggregated at low rates, dense granule number/
thrombocyte ratio was low, and in vitro bleeding time was prolonged 
in 37.5%-66.6% of patients and 33.3%-63.2% of parents (vs. 0% in 
controls). Under electron and/or light microscope, the neutrophils, 
monocytes, lymphocytes, and thrombocytes in the peripheral blood 
of both patients and parents were dysplastic and the bone marrow of 
patients revealed increased phagocytic activity, dysmegakaryopoiesis, 
and necrotic and apoptotic cells. Ultrastructurally, thrombocyte 
adhesion, aggregation, and release were inadequate. 
Conclusion: In cases of SCN, patients’ pluripotent hematopoietic stem 
cells and their non-neutropenic parents are both affected irrespective 
of the genetic defect.
Keywords: Severe congenital neutropenia, Monocytes, Lymphocytes, 
NK cells, Thrombocytes, Phagocytes, Apoptosis, Senescence, Parents, 
Family
Bulgular: Akım sitometri ile, hasta ve ebeveynlerinin monosit, 
lenfosit ve granülositlerinde apoptoz ve sekonder nekrozda belirgin 
artış olduğu ve bunun konjenital nötropeni mutasyonunun cinsi ile 
ilişkili olmadığı gösterildi. CD95 ve CD95 ligand sonuçları, apoptozun 
CD95 yolu ile olmadığını gösteriyordu. Hasta, ebeveyn ve kontrol 
olgularının lökositlerinin %25, %12,5 ve %0’ı SA-β-gal boyası ile 
boyandı. Dört olguda yapılabilen hücre siklusu analizinde üç olgunun 
lenfositlerinde G1 arresti ve apoptoz görüldü. Hastalarda HAX1 (n=6); 
ELANE (n=2); G6PC3 (n=2) ve belirlenemeyen (n=5) mutasyonlar 
saptandı. CD3, CD4 ve NK lenfositleri sırasıyla hastaların %16,6; 
%8,3; %36,4’ünde, ebeveynlerin %0, %0, %15,4’ünde, kontrolün 
%0, %0, %5,6’sında yaşa göre normal aralığın altında idi. Hasta ve 
ebeveynlerin trombositleri düşük oranda agrege oluyordu (olguların 
sırasıyla %66,6 ve %63,2’sinde, kontrolün %0’ında), kaba granül 
sayısı/trombosit oranı düşük (hasta, ebeveyn ve kontrolün %50, %35 
ve %0’ında); in vitro kanama zamanı uzun (farklı kartuşlarla olguların 
%37,5 ve %33,3’ünde ve ebeveynlerin %18,8 ve %12,5’inde) idi. Işık 
ve elektron mikroskopta hasta ve ebeveynlerin periferik kanlarındaki 
nötrofil, monosit, lenfosit ve trombositleri displastik idi; hastaların 
kemik iliğinde fagosit aktivitesinde artış, dismegakaryopoez, nekrotik 
ve apoptotik hücreler bulunuyordu. İnce yapısal olarak trombositlerde 
adezyon, agregasyon, salınım yetersiz idi. 
Sonuç: CKN’de, pluripotent hematopoietik kök hücreler ve nötropenik 
olmayan ebeveynleri genetik bozukluktan bağımsız olarak etkilenirler. 
Anahtar Sözcükler: Ciddi kongenital nötropeni, Monositler, 
Lenfositler, Trombositler, Fagositler, Apoptoz, Yaşlanma, Ebeveyn, Aile
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prior to samples being taken to eliminate drug 
effects on thrombocyte aggregation [11]. 
For lymphocyte subsets, death parameters 
(CD95, CD95 ligand, annexin V), dysmorphism, 
thrombocyte aggregation tests, mepacrine 
labeling, and in vitro bleeding time, 18, 10, 9, 
5, 5, and 9 healthy volunteers were evaluated, 
respectively. For evaluation of lymphocyte 
subsets, age-matched normal ranges for healthy 
Turkish children [12] and our laboratory for adults 
were used.
Flow Cytometric Evaluation
Peripheral blood was prepared for flow cytometric 
analysis as reported previously [8,13,14] by direct 
immunofluorescence (FAC Scan, Becton Dickinson 
CA and Beckman Coulter, USA). By combining CD45 
and CD14 with the forward and right-angle light 
scatter parameters of blood cells, the lymphocytes, 
granulocytes, and monocytes were gated (Figure 
1A). CD95, CD95 ligand, and annexin V were 
evaluated in each gate; the CD3, CD4, CD8, and 
NK cells were evaluated in the lymphocyte gates 
[13,14]. Kits from Biosciences (USA) (for CD95 and 
CD95 ligand) and Pharmingen (USA) [for annexin 
V, propidium iodide (PI), 7-aminoactinomycin D 
(7-AAD), and CD3, CD4, CD8, and NK cells] were 
used. Per sample, 10,000 cells were counted. The 
cell cycles of the lymphocytes and granulocytes 
were evaluated by the PI florescence histogram 
method [13].
Rapid Cell Senescence
The leukocytes were stained for senescence-
associated β-galactosidase (SA-β-gal kit, Sigma 
Co., Germany) as per the manufacturer’s protocols 
[15].
Mutation Analysis
Mutation analyses of HAX1, ELANE, CSF3R, G6PC3, 
and JAGN1 genes were performed by standard 
techniques (Supplemental Materials and Methods 
and Supplemental Table 1).
Evaluation of Cellular Morphology
The peripheral blood cells were evaluated by 
light (Nikon E400) and transmission electron 
microscopy (TEM) (LEO 906E) for apoptosis and 
dysplasia [8,10,14,16,17], in a blinded fashion 
(Supplemental Materials and Methods). The 
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bone marrow aspiration smears taken at admission were also 
evaluated under light microscope. Bone marrow aspiration of 
the parents could not be performed. 
Evaluation of the Thrombocytes of the Patients and the Parents
In vitro bleeding time was measured with a PFA-100 instrument 
(Dade Behring Marburg GmbH, Marburg, Germany) [18] and 
turbidimetric aggregation tests were measured with a Chrono-
Log 560 Ca aggregometer (Chrono-Log Corporation, Havertown, 
PA, USA) [18]. 
Dense granules were stained with mepacrine (1 µM, Sigma, 
St. Louis, MO, USA) [19,20] and thrombocytes were prepared 
for electron microscopic visualization of aggregation [19], as 
described previously (Supplemental Materials and Methods).
Statistics Analysis
We used SPSS 15.0 (SPSS Inc., Chicago, IL, USA) to evaluate the 
data we obtained. A normality test was performed to determine 
if the data were distributed in a normal fashion (Supplemental 
Materials and Methods). 
Results
History and Physical Examination
In our cohort, there were three pairs of siblings and one 
pair of cousins, one having coexistent amyloidosis and 
hypercholesterolemia and the other having hemoglobin 
C. Their vaccines were administered on time without any 
complications. Parents of 14 patients were 1st (n=10) or 2nd 
(n=4) degree relatives. The patients had gingival hypertrophy, 
aphthous stomatitis, decayed teeth, and tooth loss by 
26.6%, 20%, 20%, and 13.3%, respectively. None had any 
physical malformation. Several patients had monocytosis 
and thrombocytosis [21,22]. The immunoglobulin (Ig) A, G, 
and M levels of patient AG and the IgG of patient ZG were 
higher than normal, while the levels of all the other patients 
were normal. Four out of 15 SCN patients (26.6%) and 5 
of 21 parents (23.8%; 3 mothers, 2 fathers) had frequent 
nasal bleeding and easy bruising with/without menorrhagia. 
Investigations of immunoglobulin levels, which could be 
performed for ten parents, revealed normal results. The other 
characteristics of the patients and parents are presented in 
Table 1 and Supplemental Table 2.
Flow Cytometric Evaluation 
Percentage of apoptotic cells, necrotic cells, and dead cells 
(apoptotic + necrotic) in the lymphocyte, granulocyte, and 
monocyte gates of both the patients and the parents were 
higher than those of the healthy controls, while they were 
similar among the patients and parents (Figure 1). CD95 and 
CD95 ligand results were inconsistent with each other, implying 
that apoptosis was non-CD95-mediated (Table 2; Figure 1). 
The CD3, CD4, and NK cells were below the age-matched normal 
ranges in 16.6%, 8.3%, and 36.4% of the patients and 0%, 0%, 
and 15.4% of the parents versus 0%, 0%, and 5.6% of the 
controls. On the other hand, CD3 and CD8 cells were found to 
be above the age-matched normal ranges in 16.6% and 27.3% 
of the patients and in 0% and 7.7% of the parents versus 0% 
and 16.7% of the controls (Supplemental Table 3).
Olcay L, et al: Hematopoiesis in Families with Congenital Neutropenia
Figure 1. Percentage of CD95, CD95 ligand, annexin (showing 
apoptotic cells), propidium iodide (PI), or 7-aminoactinomycin D 
(7-AAD) (showing necrotic cells) and overall dead cells (apoptotic 
+ necrotic cells) in lymphocyte, monocyte, and granulocyte gates. 
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G1 arrest and apoptosis were established in one patient’s 
lymphocytes (ZG) and those of her parents while the cell cycle of 
lymphocytes in the sibling of ZG (patient AG) was normal. The cell 
cycles of the parents’ granulocytes were normal (Figures 3A-3F).
Rapid Cell Senescence
Eight patients and eight parents were evaluated. The leukocytes of 
only 2 patients (siblings AG and ZG) and their mother were stained 
with SA-β-gal by 88%, 76%, and 94%, respectively (Figures 3G, 3H, 
3I). These patients were members of a family and were evaluated 
for cell cycles at the same time (Figures 3A-3F). 
Cell Morphology
Neutrophils
The incidences of bizarre nuclei (34.0±17.4% vs. 15.2±4.7%, 
p=0.015), pseudo Pelger-Huet (PPH) and PPH-like cells (15.7±9.3 
vs. 4.1±3.3, p=0.003), striking chromatin clumping (38.1±27.7% 
vs. 11.0±9.7%, p=0.036), macropolycyte percentage (diameter ≥15 
µm) (38.71±27.46% vs. 6.44±6.00%, p=0.0001) of neutrophils, and 
neutrophil diameter (13.46±1.76 vs. 9.79±1.73, p=0.0001) were 
significantly higher in the neutrophils of the parents than those of 
the control group by light microscope.
The few neutrophils of the patients in their peripheral blood and 
bone marrow also revealed the same abnormalities, but no scoring 
could be done due to the low number.
Ultrastructural study of the patients and parents revealed that 
secondary granules of neutrophils were low in number, primary 
granules were heterogeneous in shape and size, and chromatin 
clumping and apoptosis were striking (Figures 4D, 4E, 4L, 5D, 5E, 
and 5H). 
Lymphocytes
The peripheral lymphocytes of both patients and parents revealed 
few lymphocytes with tiny cytoplasmic protrusions. Ultrastructural 
study of peripheral blood of patients and parents showed that the 
lymphocytes were abnormal or active (Figures 4G, 5F, and 5G). 
Monocytes, Macrophages, Histiocytes, and Other Phagocytes
The peripheral blood of patients and parents revealed monocytes 
with features of apoptosis, abnormal nucleus, necrosis, or 
pseudopod formation under light microscope and abnormal 
mononuclear cells under TEM with or without features of apoptosis 
(Figures 4F and 5H).
The bone marrow examination of the patients revealed many 
monocytes, macrophages, histiocytes, neutrophils, bands, 
eosinophils, and eosinophil myelocytes undergoing phagocytosis. 
Sea blue-like and Gaucher-like histiocytes in the bone marrow of 
the patients were striking. The phagocytosed cells were lymphocytes, 
235
Olcay L, et al: Hematopoiesis in Families with Congenital NeutropeniaTurk J Hematol 2018;35:229-259
Ta
bl
e 
3.
 L
ab
or
at
or
y 
pa
ra
m
et
er
s 
of
 p
at
ie
nt
s.
Pa
ti
en
t/
Se
x
M
ut
at
io
n*
Ly
m
ph
oc
yt
e 
su
bs
et
s 
(C
D3
, C
D4
, 
CD
8,
 C
D4
/C
D8
, N
K)
 a
s 
to
 a
ge
 
m
at
ch
ed
 n
or
m
al
 r
an
ge
s
De
ns
e 
gr
an
ul
e 
/ p
la
te
le
t†
 
Bl
ee
di
ng
 t
im
e 
(in
 v
it
ro
)‡
Ag
gr
eg
at
io
n 
De
fe
ct
YF
/7
 3
/1
2  
y/
M
al
e
H
AX
1  
H
om
oz
yg
ou
s 
[c
.1
30
_1
31
in
sA
 (p
.W
44
† )]
¶
N
or
m
al
2.
95
/
Co
l-
ep
i: 
15
5 
s 
Co
l-
AD
P:
 1
09
 s
N
o 
se
co
nd
ar
y 
ag
gr
eg
at
io
n 
w
it
h 
AD
P 
(2
 a
nd
 6
 µ
M
); 
hy
po
ag
gr
eg
at
io
n 
w
it
h 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
; n
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(1
 µ
g/
m
L)
 a
nd
 
ris
to
ce
ti
n 
(1
.2
5 
m
g 
/m
L)
M
N
Y/
7y
/
Fe
m
al
e
H
AX
1  
H
om
oz
yg
ou
s 
[c
.1
30
_1
31
in
sA
 (p
.W
44
† )]
¶
N
K 
lo
w
, C
D
8 
hi
gh
, o
th
er
s 
no
rm
al
1.
0/
 C
ol
-e
pi
: 1
61
 s
D
is
ag
gr
eg
at
io
n 
w
it
h 
AD
P 
(1
0 
µM
); 
no
 a
gg
re
ga
ti
on
 w
it
h 
ris
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
; n
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(1
 µ
g/
m
L)
AY
/4
y/
 F
em
al
e
(S
ib
lin
g 
of
 
M
N
Y)
H
AX
1  
H
om
oz
yg
ou
s 
[c
.1
30
_1
31
in
sA
 (p
.W
44
† )]
¶
N
or
m
al
0.
37
/C
ol
-e
pi
: 1
47
 s
N
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(1
µg
/m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
 (A
D
P 
an
d 
ep
in
ep
hr
in
 n
ot
 a
va
ila
bl
e)
 
M
K/
9y
/F
em
al
e
(s
ib
lin
g 
of
 A
Y)
H
AX
1  
H
om
oz
yg
ou
s 
 
[c
.1
30
_1
31
in
sA
 (p
.W
44
†)
] 
N
ot
 d
on
e
N
ot
 d
on
e/
N
ot
 d
on
e
H
yp
oa
gg
re
ga
ti
on
 w
it
h 
AD
P 
(1
0 
µM
) a
nd
 c
ol
la
ge
n 
(1
 µ
g/
m
L)
; n
or
m
al
 
ag
gr
eg
at
io
n 
w
it
h 
ris
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
 (e
pi
ne
ph
rin
 n
ot
 a
va
ila
bl
e)
EC
/8
y/
Fe
m
al
e
(c
ou
si
n 
of
 H
Y)
H
AX
1  
H
om
oz
yg
ou
s 
[c
.1
30
_1
31
in
sA
 (p
.W
44
† )]
¶
N
K 
lo
w
, o
th
er
s 
no
rm
al
3.
36
/N
ot
 d
on
e
N
o 
se
co
nd
ar
y 
ag
gr
eg
at
io
n 
w
it
h 
AD
P 
(2
 µ
M
); 
hy
po
ag
gr
eg
at
io
n 
w
it
h 
AD
P 
(1
0 
µM
); 
no
 a
gg
re
ga
ti
on
 w
it
h 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
; 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(1
 µ
g/
m
L)
 
H
Y/
6y
/M
al
e
(c
ou
si
n 
of
 E
C)
H
AX
1 
H
om
oz
yg
ou
s 
[c
.1
30
_1
31
in
sA
 (p
.W
44
† )]
¶
CD
8 
hi
gh
, o
th
er
s 
no
rm
al
3.
3/
N
ot
 d
on
e
N
o 
se
co
nd
ar
y 
ag
gr
eg
at
io
n 
w
it
h 
AD
P 
(2
 a
nd
 6
 µ
M
); 
hy
po
ag
gr
eg
at
io
n 
w
it
h 
co
lla
ge
n 
(1
µg
/m
L)
; n
o 
ag
gr
eg
at
io
n 
w
it
h 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
O
SK
/1
4y
/ 
M
al
e
(s
ib
lin
g 
of
 
M
eK
)
G
6P
C3
 h
om
oz
yg
ou
s, 
c.
19
4A
>C
 (p
.E
65
A)
 
N
o 
m
ut
at
io
n 
in
 H
AX
1¶
¶ / 
EL
AN
E
N
K 
lo
w
, C
D
3 
hi
gh
, o
th
er
s 
no
rm
al
2.
65
/N
ot
 d
on
e
N
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
AD
P 
(2
 a
nd
 6
 µ
M
), 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
, c
ol
la
ge
n 
(1
 µ
g/
m
L)
 a
nd
, r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
M
eK
/ 
22
y/
Fe
m
al
e 
(s
ib
lin
g 
of
 O
SK
)
G
6P
C3
 h
om
oz
yg
ou
s, 
c.
19
4A
>C
 (p
.E
65
A)
 
N
o 
m
ut
at
io
n 
in
 H
AX
1/
 E
LA
N
E
N
K 
lo
w
, C
D
3 
hi
gh
, o
th
er
s 
no
rm
al
0.
83
/ N
ot
 d
on
e
N
o 
se
co
nd
ar
y 
ag
gr
eg
at
io
n 
w
it
h 
2µ
M
 A
D
P 
an
d 
di
sa
gg
re
ga
ti
on
 w
it
h 
6µ
M
 A
D
P;
 
no
 a
gg
re
ga
ti
on
 w
it
h 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
; n
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(1
 µ
g/
m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
RT
/8
y/
M
al
e
EL
AN
E 
H
et
er
oz
yg
ou
s  
[c
.5
97
+5
G
>A
] 
N
o 
m
ut
at
io
n 
in
 H
AX
1¶
¶
N
or
m
al
1.
4/
Co
l-
ep
i:1
26
 s
 
Co
l-
AD
P:
10
0 
s
N
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
AD
P 
(2
 a
nd
 6
 µ
M
), 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
, c
ol
la
ge
n 
(1
 µ
g/
m
L)
, r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
N
BÖ
/1
0y
/ 
Fe
m
al
e
EL
AN
E 
he
te
ro
zy
go
us
 c
.4
16
C>
T 
(p
.P
13
9L
) N
o 
m
ut
at
io
n 
in
 H
AX
1/
 G
6P
C3
N
or
m
al
3.
55
/C
ol
-e
pi
:1
20
 s
N
o 
se
co
nd
ar
y 
ag
gr
eg
at
io
n 
w
it
h 
2µ
M
 A
D
P 
bu
t 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
6 
µM
 
AD
P;
 n
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
ep
in
ep
hr
in
 (1
0 
µM
/m
L)
, c
ol
la
ge
n 
(1
 µ
g/
m
L)
, a
nd
 
ris
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
BA
 / 
8 
y 
/ 
Fe
m
al
e
N
o 
m
ut
at
io
n 
in
 H
AX
1 
/ E
LA
N
E 
/ G
6P
C3
 
/ C
SF
3R
CD
3 
lo
w
, C
D
4 
lo
w
, o
th
er
s 
no
rm
al
0.
58
 / 
Co
l-
AD
P:
 1
14
 s
D
is
ag
gr
eg
at
io
n 
w
it
h 
2 
µM
 A
D
P 
bu
t 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
10
 µ
M
 A
D
P;
 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(2
 µ
g/
m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
 
(e
pi
ne
ph
rin
e 
no
t 
av
ai
la
bl
e)
AG
 / 
18
/1
2 
y 
/ 
M
al
e 
(s
ib
lin
g 
of
 Z
G
)
N
o 
m
ut
at
io
n 
in
 H
AX
1 
/ E
LA
N
E 
/ G
6P
C3
 
/ C
SF
3R
 / 
JA
G
N
1
CD
3 
lo
w
, o
th
er
s 
no
rm
al
2.
4 
/ C
ol
-A
D
P:
 1
55
 s
D
is
ag
gr
eg
at
io
n 
w
it
h 
2 
µM
 A
D
P 
bu
t 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
10
 µ
M
 A
D
P;
 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(2
 µ
g/
m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
 
(e
pi
ne
ph
rin
e 
no
t 
av
ai
la
bl
e)
ZG
 / 
32
/1
2  
y 
/ 
Fe
m
al
e 
(s
ib
lin
g 
of
 A
G
)
N
o 
m
ut
at
io
n 
in
 H
AX
1
N
ot
 d
on
e
1.
17
 / 
Co
l-
ep
i: 
11
9 
s
N
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
AD
P 
(2
 a
nd
 6
 µ
M
), 
ep
in
ep
hr
in
e 
(1
0 
µM
/m
L)
, c
ol
la
ge
n 
(1
 µ
g/
m
L)
, r
is
to
ce
ti
n 
(1
.2
5 
µg
/m
L)
AO
 / 
12
 y
 / 
M
al
e
N
o 
m
ut
at
io
n 
in
 H
AX
1 
/ E
LA
N
E 
/ G
6P
C3
 
/ C
SF
3R
 / 
JA
G
N
1¶
¶
N
ot
 d
on
e
1.
73
 / 
Co
l-
ep
i: 
21
3 
s
Co
l-
AD
P:
 1
43
 s
N
or
m
al
 a
gg
re
ga
ti
on
 w
it
h 
AD
P 
(2
 a
nd
 6
 µ
M
), 
ep
in
ep
hr
in
e 
(1
0 
µM
/m
L)
, c
ol
la
ge
n 
(1
 µ
g/
m
L)
, a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
KŞ
 / 
12
 y
 / 
M
al
e§
N
ot
 d
on
e
N
ot
 d
on
e
N
ot
 d
on
e 
/ C
ol
-e
pi
: 1
61
 s
 
Co
l-
AD
P:
 7
9 
s
N
o 
se
co
nd
ar
y 
ag
gr
eg
at
io
n 
w
it
h 
2 
µM
 A
D
P 
bu
t 
no
rm
al
 a
gg
re
ga
ti
on
 w
it
h 
6 
µM
 
AD
P;
 h
yp
oa
gg
re
ga
ti
on
 w
it
h 
co
lla
ge
n 
(1
 µ
g/
m
L)
 a
nd
 r
is
to
ce
ti
n 
(1
.2
5 
m
g/
m
L)
*P
er
ip
he
ra
l b
lo
od
 c
el
ls
; †
Co
nt
ro
l v
al
ue
s 
fo
r 
de
ns
e 
gr
an
ul
e 
/ p
la
te
le
t: 
2.
78
-3
.8
2;
 ‡
N
or
m
al
 v
al
ue
s 
fo
r 
in
 v
itr
o 
bl
ee
di
ng
 t
im
e 
w
ith
 c
ol
la
ge
n-
ep
in
ep
hr
in
e 
(C
ol
-e
pi
) c
ar
tr
id
ge
s:
 8
5-
15
7 
s;
 w
ith
 c
ol
la
ge
n-
AD
P 
(C
ol
-A
D
P)
 c
ar
tr
id
ge
s:
 6
5-
12
5 
s;
 § L
os
t 
to
 fo
llo
w
-u
p;
 ¶
15
9T
>
C 
ho
m
oz
yg
ou
s 
po
ly
m
or
ph
is
m
 in
 e
xo
n 
2 
of
 H
AX
1 
ge
ne
; ¶
¶ 1
59
T>
C 
he
te
ro
zy
go
us
 p
ol
ym
or
ph
is
m
 in
 e
xo
n 
2 
of
 H
AX
1 
ge
ne
; #
ne
w
 m
ut
at
io
n 
(in
 s
ub
m
is
si
on
).
236
Turk J Hematol 2018;35:229-259Olcay L, et al: Hematopoiesis in Families with Congenital Neutropenia
Figure 2. FACS gating and flow cytometric graphics of annexin and PI/7-AAD of lymphocytes, monocytes, and granulocytes of patients 
with congenital neutropenia and their parents. 2A1 and 2A2: Those of patients with HAX1 mutation (YF, EC, AY, MNY, HY) and their 
parents. The mother and father of AY, MY, and HY and the mother of EÇ were heterozygous for HAX1. 
Figure 2.A1
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Figure 2. Continued. FACS gating and flow cytometric graphics of annexin and PI/7-AAD of lymphocytes, monocytes, and granulocytes 
of patients with congenital neutropenia and their parents. 2A1 and 2A2: Those of patients with HAX1 mutation (YF, EC, AY, MNY, HY) 
and their parents. The mother and father of AY, MY, and HY and the mother of EÇ were heterozygous for HAX1. 
Figure 2.A2
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Figure 2. Continued.  FACS gating and flow cytometric graphics of annexin and PI/7-AAD of lymphocytes, monocytes, and granulocytes 
of patients with congenital neutropenia and their parents. 2B: Those of RT with ELANE mutation and his parents and parents of NBÖ 
with ELANE mutation. The cells of patient NBÖ could not be evaluated. Neither of the parents had ELANE mutation in peripheral 
lymphocytes or buccal mucosa. 
Figure 2.B
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Figure 2. Continued. FACS gating and flow cytometric graphics of annexin and PI/7-AAD of lymphocytes, monocytes, and granulocytes 
of patients with congenital neutropenia and their parents. 2C: Those of two siblings with congenital neutropenia with unidentified 
mutation and their parents (AG, ZG). 2D: Those of one of the healthy volunteers. 
Figure 2.C
Figure 2.D
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Figure 3. Cell cycle patterns of two sibling patients, their mother, and their father: A) normal cell cycle (patient AG, lymphocyte; sibling 
of ZG); B) G1 arrest and pre-G1 peak showing apoptosis (patient ZG; sibling of AG); C) G1 arrest and apoptosis (mother DG, lymphocyte); 
D) normal cell cycle (mother DG, granulocyte); E) G1 arrest and apoptosis (father SG, lymphocyte); F) normal cell cycle (father SG, 
granulocyte) (the patients’ granulocytes could not be evaluated due to granulocytopenia). G-H-I: The leukocytes of two sibling patients 
and their mother stained by SA-β-gal, as blue granules, from peripheral blood culture (400x). The leukocytes of patient AG (G), patient 
ZG (H), and their mother DG (I). These patients were members of a family evaluated for cell cycles.
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erythroblasts, or apoptotic cells. Necrosis of cells that had 
phagocytosed other cells was also evident (Figures 6A, 6B, 6C). 
Megakaryopoiesis
Megakaryocytes with asynchrony in nucleo-cytoplasmic 
maturation or those undergoing emperipolesis or transformed/
transforming to naked megakaryocyte nuclei were striking. 
Additionally, naked megakaryocyte cytoplasm just after 
completing thrombocyte release, many megakaryoblasts, and 
necrotic, apoptotic, or dysplastic megakaryocytes were also seen 
in the bone marrow examinations of the patients (Figures 6A, 
6B, 6C). 
Thrombocytes and Thrombocyte Functions
Thrombocytes with heterogeneous size, abnormal shape, 
and/or giant forms were observed on the peripheral blood 
smears of both the parents and patients. Giant and dysplastic 
thrombocytes were also evident in many patients’ bone marrow 
under light microscope (Figures 6A, 6B, 6C). 
The mean dense granule number per thrombocyte was 2.01±1.19 
(0.37-3.55) in the patients (n=12), 2.27±1.33 (0.22-4.47) in 
the parents (n=20), and 3.32±0.40 (2.78-3.82) in the healthy 
controls (n=5), and these were comparable with each other 
(p=0.147). However, the percentage of patients, parents, and 
controls who had fewer than 2 dense granules per thrombocyte 
was 50%, 35%, and 0% respectively (Supplemental Figure 1).
Ultrastructural examination showed that the thrombocytes had 
a reduced number of dense granules that were heterogeneous 
in size, shape, and composition. The open canalicular system 
(OCS) was enlarged and contained unevacuated components in 
patients (Figures 4H, 4I, 4J, 4K, and 7A - Case 2) and parents 
(Figures 5G and 5I).
In vitro bleeding time was prolonged in patients and parents 
by 37.5% and 18.8% with collagen-epinephrine cartridges and 
by 33.3% and 12.5% with collagen-ADP cartridges, respectively, 
vs. 0% in the control group with both cartridges. While in 
vitro bleeding times in patients and parents were comparable 
(p=0.293 and 0.233, respectively), only the in vitro bleeding 
time with collagen-ADP in patients was longer than in the 
control (p=0.031) (Supplemental Table 4).
Up to 63.6% and 44.4% of the aggregation results performed 
with various reactive substances in patients and their family 
members displayed abnormalities (Table 3; Supplemental Tables 
5 and 6). 
Thrombocyte aggregation at the 2nd, 8th, and 14th minutes under 
TEM (Figure 7) revealed a lack of adhesion and a lack of or 
inadequate secretion as also seen in Figures 4H, 4I, 4J, 4K, 5G, 
and 5I, with delayed or defective centralization, development 
of pseudopods, and/or secretion, abnormal degranulation, 
dissociation phenomenon [23,24], and abnormal amoeboid 
cytoplasmic protrusions (Supplemental Results).
There was inconsistency between the presence of hemorrhagic 
diathesis and abnormality of laboratory tests (aggregation 
tests, dense granule number in thrombocytes, in vitro bleeding 
time, thrombocyte ultrastructure) and vice versa. Not all these 
abnormalities coexisted all together (Table 3; Supplemental 
Table 6).
Genetic Mutations
Fourteen of 15 patients and 9 of 21 parents were evaluated for 
genetic mutations. Patients had homozygous [c.130_131insA 
(p.W44*)] mutation in the second exon of the HAX1 gene (n=6), 
heterozygous ELANE mutations [c.597+5G>A and c.416C>T 
(p.P139L) (n=2)], and homozygous G6PC3 mutation [c.194A>C 
(p.E65A), n=2], which is a novel mutation in the literature and 
is predicted to be disease-causing by SIFT and MutationTaster 
in silico analysis software [in submission]. Five had unidentified 
mutations. No tested patient had CSF3R mutation. ELANE 
c.597+5G>A splicing mutation was predicted to be disease-
causing by NNSPLICE, GeneSplicer, and Human Splicing Finder 
in silico prediction tools. 
Patients with HAX1 displayed coexistent homozygous 
c.159T>C polymorphism in the second exon of the HAX1 
gene. Three patients with other mutations were heterozygous 
for this polymorphism (Tables 1 and 3). Both the mother and 
father of AY, MNY, and HY and the mother of EÇ were found 
heterozygous for HAX1 [c.130_131insA (p.W44*)]. The parents 
of the two patients with heterozygous ELANE mutation revealed 
no mutation in the ELANE gene and their buccal mucosa cells 
did not reveal mosaicism. 
Discussion 
In this study, we showed that non-granulocytic blood cells were 
also affected and that morphologic and functional changes 
occurred in patients with SCN and in their non-neutropenic 
family members, and cell death mechanisms other than 
apoptosis also operated.
Apoptosis and Secondary Necrosis in Granulocytic and Non-
Granulocytic Cells
It has been reported that in SCN and other neutropenic states, 
accelerated apoptosis of bone marrow granulocytic progenitor 
cells [1,2,6,25,26,27,28,29,30,31] and lymphocyte apoptosis 
[7,8] took place through different mechanisms. In our study, 
apoptosis was demonstrated not only in granulocytes and 
lymphocytes but also in monocytes by elevated annexin V, 
ultrastructural appearance, and a pre-G1 peak in cell cycle 
analysis. The absence of a pre-G1 peak is not enough to exclude 
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Figure 4. Electron microscopic images of the blood cells of the patients. A) Normal lymphocyte (16700x), B) normal neutrophil (3597x), C) 
normal thrombocyte (10000x), D) patient EC (with HAX1 mutation) (12930x), E) patient NBÖ (with ELANE mutation) (12930x), F) patient 
OSK (with G6PC3 mutation) (10000x), G) patient EC (with HAX1 mutation) (16700x), H) patient EC (with HAX1 mutation) (35970x), I) 
patient MeK (with G6PC3 mutation) (46460x), J) patient MNY (with HAX1 mutation) (12930x), K) patient NBÖ (with ELANE mutation) 
(27800x), L) patient MeK (with G6PC3 mutation) (14000x) (N: nucleus; thick arrow: primary granule; thin arrow: secondary granule; OCS: 
open canalicular system; d: dense granule; *: segment of non-apoptotic nucleus; arrow head: fusion of granules; O: autophagosome). 
Decreased number of secondary granules in the neutrophils (Figures 4D, 4E), which were abnormal in shape (4L). Primary granules 
that were irregular in shape (Figures 4E, 4L) or large (Figure 4D) and had a tendency to combine and condense (Figure 4E). Chromatin 
clumping in nuclei (Figure 4D) and apoptosis (Figure 4E). An active lymphocyte (Figure 4G). Abnormal giant mononuclear cell with 
abundant mitochondria and autophagic vacuole (Figure 4F). Dense granules in platelets, which were large and giant (Figure 4H), reduced 
in number (Figure 4H), in different shapes and dimensions (Figures 4H, 4J, 4K) with varying components (Figure 4I). Enlarged open 
canalicular system due to unevacuated ingredients (Figures 4H, 4I, 4J, 4K).
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Figure 5. Electron microscopic images of the blood cells of the parents. A) Normal lymphocyte (16700x), B) normal neutrophil (3597x), C) 
normal thrombocyte (10000x), D) mother of AO (with unidentified mutation) (SO) (12930x), E) mother of AO (with unidentified mutation) 
(SO) (12930x), F) father of MeK and OSK (with G6PC3 mutation) (MK) (16700x), G) father of MeK and OSK (with G6PC3 mutation) (MK) 
(10000x), H) father of MeK and OSK (with G6PC3 mutation) (MK) (21560x), I) father of MNY and AY (with HAX1 mutation) (AhY) (27000x) 
(N: nucleus; thick arrow: primary granule; thin arrow: secondary granule; OCS: open canalicular system; d: dense granule; *: segment of 
non-apoptotic nucleus; arrow head: fusion of granules; O: autophagosome). Decreased number of secondary granules in the neutrophils 
(Figures 5D, 5E). Primary granules in irregular shape (Figure 5D). Chromatin clumping in nuclei (Figure 5D) and apoptosis (Figures 5D, 5E, 
5H). Abnormal lymphocytes (Figures 5F, 5G). Dense granules in platelets, which were large and giant (Figure 5I). Open canalicular system 
enlarged due to unevacuated ingredients (Figures 5G, 5H, 5I).
Olcay L, et al: Hematopoiesis in Families with Congenital Neutropenia
244
Turk J Hematol 2018;35:229-259Olcay L, et al: Hematopoiesis in Families with Congenital Neutropenia
Figure 6.A
Figure 6.B
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Figure 6. Features of some bone marrow cells (megakaryocytes, thrombocytes, monocytes, macrophages, histiocytes, other phagocytes, 
and apoptotic/necrotic cells) of the patients by light microscope. 6A: Features of some bone marrow cells from the patients with HAX1 
mutation. i, xxvii, xxviii): Patient AY; ii) Patient EÇ; iii, iv, viii, xvi, xxx) Patient MNY; v, vi, x, xii, xv, xvii, xviii, xxi, xxii, xxiii, xxiv, xxvi) 
Patient MK; vii, xiv, xxix) Patient YF; xi, xii, xiii, xix, xx, xxv) Patient HY (1000x). i) Giant thrombocyte; ii) dysplastic thrombocytes; iii, xi, xii, 
xiii, xiv) Megakaryoblasts with nucleo-cytoplasmic asynchrony; iv, v, vi, ix) senescent megakaryocytes undergoing the process of being naked 
megakaryocyte nucleus and naked megakaryocyte cytoplasm, just as producing (v, vi) or after completing production of thrombocytes (iv, 
vii, ix), with emperipolesis of other bone marrow cells (iv, ix); viii) Abnormal megakaryocyte; x) a megakaryocyte that has just developed 
into a naked megakaryocyte nucleus and naked megakaryocyte cytoplasm. xv) A macrophage full of fat (Gaucher-like cell); xvi, xix, xxii, 
xxiv) monocytes that are phagocytosing various mononuclear cells; xx) a monocyte phagocytosing an apoptotic cell; xvii, xxi, xxiii) other 
phagocytes like a neutrophil (xvii), eosinophilic myelocyte (xxi), and stab (xxiii) that are phagocytosing other bone marrow cells; xxv) A 
megakaryocyte undergoing necrosis; xxix, xxx) megakaryocytes undergoing apoptosis; xxvi) a monocyte that had performed phagocytosis 
and is undergoing necrosis; xxvii) a monocyte undergoing necrosis; xxviii) an eosinophilic myelocyte with an apoptotic body attached to 
the cell. 6B: Features of some bone marrow cells from the patients with ELANE mutation. i, iii, iv, vii, viii, ix, x, xi) Patient NBÖ (1000x); 
ii, iv, vi) Patient RT (1000x). i) A degenerating dysplastic megakaryocyte; ii) a mononuclear megakaryocyte undergoing emperipolesis; iii) a 
giant thrombocyte; iv, v) megakaryoblasts with nucleocytoplasmic asynchrony; vi) naked megakaryocyte nuclei that could not transform to 
unique nuclei. vii, viii) Histiocytes that phagocytosed many bone marrow cells; ix) A megakaryocyte that is just about to undergo necrosis; 
x) a ghost-like cell degenerating through secondary necrosis; xi) a necrotic megakaryocyte. 6C: Features of some bone marrow cells from 
the patients with unidentified mutations. i, v, vii, viii, xi, xv, xx, xxi) Patient AO; iii, vi, ix, x, xiii, xiv, xvi, xviii, xix, xxii, xxiii, xxiv) Patient 
ZG; iv) Patient BA; ii, xii, xvii) Patient KŞ (1000x, except Figure vi, which is presented at 400x). i) A megakaryocyte with nucleo-cytoplasmic 
asynchrony; ii, iii) senescent megakaryocytes undergoing the process of transformation to naked megakaryocyte nucleus and naked 
megakaryocyte cytoplasm, just as producing thrombocytes (ii) or after finishing production of thrombocytes (iii) or with emperipolesis (iii); 
iv) a giant thrombocyte; v, viii, ix) megakaryoblasts; vii) a megakaryocyte that is just transforming to naked megakaryocyte nucleus and 
naked megakaryocyte cytoplasm; vii) a naked megakaryocyte nucleus; x) a dysplastic megakaryocyte with two nuclei and scanty cytoplasm 
but thrombocyte production; xi, xii, xvi, xix) Monocytes (xi, xiv), macrophages (xii, xvi, xix) that had phagocytosed or are phagocytosing 
bone marrow cells with eosinophilic cytoplasm (xix) or pseudopods (xiv); xv, xx, xxi) histiocytes that have been phagocytizing bone marrow 
cells (xv, xx) and/or consist of basophilic debris, which gives the appearance of sea blue-like histiocytes (xv, xx, xxi); xvii, xviii) phagocytosis 
of other phagocytes like eosinophils (xviii) or eosinophil metamyelocytes (xvii); xxiii, xxiv) Macrophages with normal (xxiii) or eosinophilic 
(xxiv) cytoplasm that had performed hemophagocytosis and are undergoing necrosis now.
Figure 6.C
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Figure 7. Electron microscopic images of the aggregating thrombocytes after addition of 2 µM ADP. All bars are 500 nm. Case 1 (patient 
BA, with unidentified mutation): A) 2nd minute of aggregation: Thrombocytes are seen to have become close to each other; the granules 
(G) have centralized; open canalicular system is enlarged (↑); one dense granule is visible in enlarged open canalicular system (*). B) 
8th minute of aggregation: Platelets are still distant from each other. There are no platelets that fit tightly to each other. However, 
the granules (G) have centralized and have discharged their ingredients. Open canalicular system is enlarged and consists of residual 
secretion (↑). There are a few granules that have not evacuated their ingredients yet. C) 14th minute of aggregation: The platelets are seen 
to have become closer but they are still apart from each other. The open canalicular system is enlarged and consists of some secretion 
(↑). There are and there are not undischarged granules (G) in thrombocytes 1 and 2, respectively. Case 2 (Patient ZG, with unidentified 
mutation): A) 2nd minute of aggregation: Thrombocytes are seen to be apart from each other; the granules (G) have fairly centralized 
and are intact. B) 8th minute of aggregation: The granules (G) are larger than normal and increased in number. They have centralized but 
have not discharged their contents yet. Pseudopods have developed. The open canalicular system has not enlarged yet (↑). C) 14th minute 
of aggregation: The thrombocytes have not adhered to each other yet. The dense granules are distributed throughout the cytoplasm 
but the majority have not discharged their contents yet. Upper thrombocyte: The granules (G) are very large and increased in number. 
None of them have evacuated their contents. Open canalicular system (↑) is apparent. Normal Control: A) 2nd minute of aggregation: 
Thrombocytes are seen to fit tightly together and display abundant pseudopods. They have released almost all of their granules. B) 8th 
minute of aggregation: Thrombocytes fit tightly together. They have degranulated completely, except a few.
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apoptosis [32]. Inconsistent elevations in CD95 and CD95 ligand 
pointed at a non-CD95-mediated apoptosis.
Only in the case of excessive apoptosis, during which the 
capacity of phagocytes to engulf apoptotic cells is reduced, do 
the uncleared apoptotic cells and fragments undergo secondary 
necrosis (delayed apoptotic clearance), which can provoke 
inflammation [33]. Our flow cytometric and microscopic 
findings revealed that apoptotic and necrotic cells coexisted 
in three cell lines in patients irrespective of the type of SCN 
mutation, and in their parents. 
We think that in our patients apoptotic and necrotic cells in the 
myeloid lineage activated macrophages and other phagocytes 
extensively (Figures 6A, 6B, 6C), inducing secretion of TNF-
alpha, IL-1, IL-6, and IL-12 by activated macrophages, the latter 
exacerbating macrophage activation through stimulating IFN-
gamma production [34,35]. High levels of TNF-alpha [36,37] 
in SCN patients and their non-neutropenic parents [36] and 
increased capacity of stimulated monocytes to produce TNF-
alpha on stimulation through certain toll-like receptors [38,39] 
were reported before.
We consider the apoptosis in the non-granulocytic cells to be 
due to the high TNF-alpha levels, which can give rise to apoptosis 
in neutrophils [40,41], lymphocytes [42,43], monocytes [44], 
and thrombocytes [45] in various conditions [46] through TNF 
alpha-TNFR1 interaction (Supplemental Discussion, Text 1).
Cytopenia in Non-Granulocytic Cells and RCS
Absence of lymphopenia (except 1 case), monocytopenia, and 
thrombocytopenia (Table 1; Supplemental Table 2) is apparently 
due to good compensation of the bone marrow of both the 
patients and the parents. 
However, it was striking that both patients and their parents 
had quantitative abnormalities in T lymphocytes and NK cells, 
regardless of the type of the SCN mutation carried by the 
patients. 
Abnormalities in B, cytotoxic T, NK, NKT, Th2, and Th7 cells 
were reported in SCN with GFI-1 mutation, albinism-
neutropenia syndromes, and Wiskott-Aldrich syndrome (WAS) 
[2,47,48,49,50,51]. None of our cases were clinically compatible 
with WAS or albinism-neutropenia syndromes. However, 2 SCN 
patients with WAS mutation were reported to have a reduced 
number of NK and CD4+ cells [7]. Interestingly, SCN patients 
with ELANE and unidentified mutations were reported to have 
normal numbers of NK cells that were less mature than those 
of normal controls [52]. NK cell deficiency and dysfunction 
was reported in some chronic neutropenia patients with 
morphological abnormalities [53]. In our cases, patients with 
NK levels lower than the normal range for age had HAX1 
(n=2) and G6PC3 (n=2) mutations while patients with low CD3 
(n=2) and CD4 (n=1) levels had unidentified mutations (Table 
3). Mature neutrophils are reportedly necessary for NK cell 
development [52]. Reduced mature neutrophils may account 
for low levels of NK cells in the patient group but the reasons 
why not all SCN patients had low NK cells and why the parents 
who had low NK levels were not neutropenic require further 
investigations.
That the patients with low CD3+ and CD4+ lymphocytes (AG, 
ZG) were those with β-gal positivity of leukocytes suggests 
that the continual presence of circulating pro-inflammatory 
factors secreted by activated macrophages kept the immune 
system in a state of chronic low-level activation, giving rise to 
immunosenescence through loss of telomeric DNA with each S 
phase and therefore a decline in the number of T lymphocytes 
and no change or decline in overall lymphocyte and NK cells [54] 
during which inflammatory mediators secreted by senescent 
cells themselves contributed to immunosenescence [55,56] (we 
could not evaluate B lymphocytes) (Supplemental Discussion, 
Text 2). 
The presence of apoptosis together with RCS was reported in 
SCN [8] and in cell lines that had been administered cytotoxic 
drugs [57]. These cases (ZG and parents) in which individuals had 
not consumed cytotoxic drugs and were exposed to radiation 
may carry an unknown DNA-disrupting factor.
Cellular senescence is the state of irreversible cell cycle arrest, 
predominantly in the G1 phase [57,58,59,60,61,62,63,64], 
being dependent on (replicative senescence) or independent 
of telomeres (RCS) [60,61]. The latter is due to inappropriately 
expressed pro-proliferative genes [63], oncogenic mutations 
[62], DNA-damaging drugs, or gamma irradiation [57,58]. 
The senescence-like phenotype is characterized by reorganization 
of heterochromatin [65,66], formation of fragmented nuclei, 
polyploidy, and enlarged and flattened cell shape, along with 
expression of SA-β-gal positivity [15,57] and alterations in the 
cell cycle [65]. 
Dysplasia of Hematopoietic Cells
In our study, as reported previously [8,10], dysplasia was noted 
not only in the neutrophil series but also in the monocyte, 
megakaryocyte, lymphocyte, and eosinophil series in all 
patients and parents to various degrees. Some dysplasia 
parameters overlap with the senescence phenotype; however, 
restriction of RCS to a few cases in our study showed that 
RCS only partially affected the development of dysplasia. Our 
previous studies point at the role of inflammatory cytokines 
to cause dysplasia [36,37] in patients with autoimmune 
disorders, acute infections, and hemophagocytic histiocytosis 
[67,56]. The pro-inflammatory cytokines secreted by activated 
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macrophages can destroy the bone marrow microenvironment 
and hematopoietic stem cell niches by activating innate 
immune cells [55] and give rise to hematopoietic stem 
cell dysfunction, dyshematopoiesis, and thus dysplastic 
hematopoietic cells. 
Morphologic abnormalities due to abnormal differentiation 
in myeloid cells are also encountered in congenital, cyclic, 
dysgranulopoietic neutropenia cases [7,10,66,68] with or 
without the WAS, GFI-1, and G6PC3 mutations [1,7], in 
myelodysplastic syndrome, and in a number of non-malignant 
disorders [16,67]. 
Dysmegakaryopoiesis and Hemorrhagic Diathesis
That the presence of nearly no normal megakaryocytes in 
our patients and that nearly all megakaryocytes displayed 
characteristics of naked megakaryocyte nuclei, emperipolesis, 
or abnormal morphology like peripheral vacuolization 
(showing non-classical apoptosis: para-apoptosis) and 
directly destructed megakaryocytes (showing necrosis) and 
presence of many stage 1 megakaryocytes (megakaryoblasts), 
some of which were aberrantly releasing thrombocytes, imply 
defective megakaryocyte maturation, heavy intramedullary 
premature cell death of megakaryocytes, and increased 
megakaryopoiesis [14,69,70,71,72,73] (Supplemental 
Discussion, Text 3). 
Defective maturation in megakaryocytes is also expected to 
be due to the increased levels of pro-inflammatory cytokines, 
which can destroy the bone marrow microenvironment and 
hematopoietic stem cell niches [55]. Therefore, thrombocytes 
derived from megakaryocytes with defective maturation are 
also expected to be functionally abnormal. 
Hence, in our cases, we noted a combination of thrombocyte 
functional defects and in a few of them a low number of 
mepacrine-labeled dense granules reminiscent of a delta 
storage pool defect. The ultrastructural view of aggregating 
thrombocytes (Figure 7; Supplemental Discussion, Text 3) 
may reflect defective transmission. From all these aspects, the 
findings of our patients resemble the thrombocyte disorders 
encountered in leukemia, refractory anemia, cystinosis, and 
others [19,23,24,74,75]. 
Hemorrhagic diathesis is a common finding of albinism-
neutropenia syndromes like Chediak-Higashi syndrome, 
Hermansky-Pudlak syndrome type 2, Griselli’s syndrome type 2, 
Cohen’s syndrome, and p14 deficiency [51] but has not been 
reported in SCN [76] before. 
Our results, at the same time, confirmed that not all patients with 
thrombocyte aggregation defects display laboratory evidence 
[18,77,78] and the most reliable tool to show thrombocyte 
aggregation defect is electron microscopic evaluation [78,79,80]. 
Parents
No parent had cytopenia; however, apoptosis and secondary 
necrosis to various degrees in granulocytes, monocytes, and 
lymphocytes with the presence of dysplasia, decreased NK 
cells, and abnormalities in thrombocyte functions in most of 
the parents and RCS in one suggest that the parents were also 
affected by the same genetic abnormality but the cell loss was 
well compensated by the proliferating compartment. However, 
only the parents of patients with ELANE and those of most 
patients with HAX1 could be evaluated genetically. 
For the parents of the patients with homozygous HAX1 
mutation (AY, MNY, HY, EÇ) who were heterozygous for the same 
mutation, we think that cell loss took place through one mutant 
allele, just like in their children. The apoptotic hematopoietic 
cells (lymphocytes, neutrophils, monocytes) were the mutant 
cells that were lost early [81,82], but normal hematopoiesis 
compensated for the cell loss when the other allele was normal. 
As for the parents of patients with ELANE mutation (RT, NBÖ), 
the absence of ELANE mutation in the parents’ peripheral blood 
cells led us to consider that the parents were either mosaic for 
the mutation or actually normal and their children were sporadic 
cases of ELANE mutation. Hence, a number of phenotypically 
healthy parents were shown to harbor somatic [83], only 
germline [3], or both somatic and germline [84] mosaicism of 
ELANE mutation. On the other hand, most of the sporadic cases 
of SCN were reported to have ELANE mutations [85].
That we could not detect mosaicism in the buccal mucosa cells 
of the parents does not rule out mosaicism definitively. A search 
for mutant alleles in various other cell types like skin or sperm 
of the father, preferably using more sensitive mutation analysis 
methods, might have proved mosaicism, like in the reported 
cases [3,86] in which the mutant allele was negative in DNA 
from neutrophils, buccal mucosa, and/or lymphocytes and was 
detected only in spermatozoa. However, the parents felt uneasy 
about being tested any further. 
Additionally, that the parents of patient RT had normal blood 
cell counts but high cell death parameters in lymphocytes, 
granulocytes, and monocytes like the parents with heterozygous 
HAX1 suggested that they were very probably affected by the 
same mutation in the same gene, ELANE, as their children. 
However, we cannot exclude the possibility that patient RT was 
a sporadic case of ELANE mutation and did not additionally 
harbor any other untested/unidentified neutropenia mutation 
[87] and that his parents were carriers of this mutation. On 
the other hand, similar death parameters in the hematopoietic 
cells of the parents of NBÖ to those of the controls suggested 
that the ELANE mutation in NBÖ could be sporadic. As a 
second possibility, both of the parents of NBÖ might have 
cyclic hematopoiesis with consecutive normal and abnormal 
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hematopoiesis [88], just like in the mother of a patient with 
JAGN1 mutation who we followed before [8,10, unpublished 
data]. However, we could not exclude an unidentified mosaicism 
for the parents of NBÖ definitively due to the same reasons. 
As for the parents of patients with G6PC3 (OSK, MeK) and 
unidentified mutations (AO, BA, AG, ZG, KŞ), only two siblings 
with unidentified mutation (AG, ZG) and their parents could be 
evaluated for cell death parameters and both the parents’ blood 
cells (lymphocytes, granulocytes, monocytes) showed apoptosis 
and necrosis similar to that of their children. Therefore, we 
think that the parents of patients with other recessive SCN gene 
mutations (like G6PC3 and at least some of the unidentified 
mutations) might be heterozygous for the same genetic defect, 
like in the parents who were heterozygous for HAX1.
We think that the modifying effects of other genes or factors 
[3,89] and any other accompanying neutropenia mutations [87] 
and many other factors that play roles in the transmission of 
disease, including the 159T>C polymorphism in the same exon 
of HAX1 mutation in patients with HAX1 and other mutations 
as in other cases [90,91], both in the patients and parents, need 
to be evaluated in further studies.
The gingival enlargement and oral aphthae of the parents in the 
present study were thought to be possibly due to dysfunctional 
neutrophils, which were dysplastic at the same time, like a non-
neutropenic mother of a patient with JAGN1 mutation who we 
followed before and had apoptosis in addition to morphological 
and functional abnormalities in neutrophils, lymphocytes, and 
thrombocytes with low levels of myeloperoxidase and defective 
chemotaxis [8,10, unpublished data].
Easy bruising and gingival bleeding of the parents were 
attributed to defective thrombocyte functions stemming from 
defective megakaryopoiesis. 
We attribute apoptosis and secondary necrosis in the myeloid 
lineage of the non-neutropenic parents to the aforementioned 
genetic abnormalities relevant to SCN, while those in the non-
granulocytic cells to the high TNF-alpha levels [36] that can 
give rise to apoptosis in blood cells [40,41,42,43,44,45,46], as 
discussed for children with SCN. 
Conclusion
Apoptosis and secondary necrosis in non-granulocytic cell lines, 
dysplasia of blood cells with/without RCS, and disturbances in 
lymphocyte subsets and thrombocyte functions were observed in 
patients with congenital neutropenia and their non-neutropenic 
parents. Additionally, bone marrow of the patients showed 
increased phagocytic activity and striking dysmegakaryopoiesis. 
(Table 4). This study shows that abnormalities in lymphocyte 
subsets and hemorrhagic diathesis are not restricted to albinism-
neutropenia syndromes, as current wisdom holds, but are also 
encountered in SCN. 
Moreover, our findings suggest that the pluripotent 
hematopoietic stem cells in SCN are defective irrespective of 
the genetic etiology, in contrast to the current thinking that 
understands the main defect as residing in the progenitor 
myeloid cells [1,2,6], and myeloid transcriptional factors [92,93]. 
Study Limitations
The main limitation of our study was that not all sub-studies 
could be performed for all cases due to daily limitations of our 
laboratory facilities. Including idiopathic neutropenic patients 
as a separate control group could have helped evaluate the 
results more extensively, although these patients were beyond 
the scope of this study. In spite of this, we believe that our 
results may lead to further in vivo and in vitro studies involving 
pluripotent hematopoietic stem cells in SCN so as to better 
understand the underlying physiopathology. Additionally, the 
presence of the same abnormalities in non-neutropenic parents 
shows that the phenotype-genotype relationship is another 
field that requires further evaluation. 
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Appendix: Supplemental Materials and Methods
Mutation Analysis 
Mutation analyses of the HAX1, ELANE, CSF3R, and G6PC3 genes were performed by standard techniques using a DNA sequencing kit 
(PerkinElmer, Foster City, CA, USA) and the ABI Prism 3100 sequence analyzer (Applied Biosystems, Foster City, CA, USA).
Reference accession number of the genes
HAX1 (NM_006118)
ELANE (NM_001972)
CSF3R (NM_156039)
G6PC3 (NM_138387)
JAGN1 (NM_032492)
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Evaluation of Cellular Morphology 
The peripheric blood cells were evaluated by light (Nikon Eclipse E400, 
Nikon Corporation, Japan) and transmission electron microscope (TEM) 
(LEO 906E, Zeiss, Germany) for apoptosis and dysmorphism [1,2,3,4], 
in a blinded fashion. One hundred neutrophils of the parents (except 
YF’s mother whose peripheral blood smear enabled us to evaluate 
only 50 neutrophils) and control group were scored for dysmorphism 
under light microscope (1000x). Each dysmorphic feature shown by 
an individual neutrophil was given one score and the total score for a 
definite dysmorphic feature was presented as ‘%’. Only for YF’s mother 
the total score for a definite dysmorphic feature was multiplied by 
two. The patients’ neutrophils could not be scored due to neutropenia. 
The photographs of the representative cells with dysmorphic features 
under electron microscope were taken and presented. 
Evaluation of the Thrombocytes of the Patients and the Parents 
In vitro bleeding time: This was measured by a PFA−100 instrument 
(Dade Behring Marburg GmbH, Marburg, Germany) using collagen-
epinephrine and/or collagen-ADP cartridges [5]. 
Turbidimetric aggregation tests: A Chrono-Log 560 Ca 
aggregometer was used with minor modifications (Chrono-Log 
Corporation, Havertown, PA, USA) [5]. Thrombocyte aggregation 
was studied with collagen (1 and 2 μg/mL), ristocetin (1.25 mg/mL), 
ADP (2, 6, 10 μM), and epinephrine (10 μM). 
Mepacrine labeling of dense granules: Thrombocyte-rich plasma was 
prepared and stained with mepacrine (1 μM; Sigma, St. Louis, MO, 
USA) as described previously [6,7]. The greenish-yellow fluorescent 
dense granules were visualized under a fluorescent microscope 
(Zeiss Axoscope; Zeiss, Thornwood, NY, USA). The dense granules 
were counted in 84-106 platelets for each sample. The results were 
presented as the mean dense granule number per thrombocyte [6,7].
Electron microscopic evaluation of aggregation: After adding 2 μM 
ADP to thrombocyte-rich plasma obtained from two patients (BA, 
ZG), samples were removed at the 2nd, 8th, and 14th
 
minutes and 
were prepared for TEM [6].
Statistics
We used SPSS 15.0 to evaluate the data we obtained (SPSS Inc., 
Chicago, IL, USA). A normality test was performed to determine 
if the data were distributed in a normal fashion. To compare 
evenly and unevenly distributed data, we used the independent 
samples t-test and the Mann-Whitney U test (for two groups) and 
One-way ANOVA and the Kruskal-Wallis H test with Bonferroni 
correction (for more than two groups). We used the Scheffe test 
in the one-way ANOVA testing to determine which groups had 
differences between themselves. One-sample t-tests were used 
to evaluate whether the means of the variables differed from 
the means of the reference group. Values of p<0.05 and p<0.017 
were considered significant for inter-group comparison and the 
Kruskal-Wallis H test, respectively.
Supplemental Results 
Ultrastructural View of Aggregating Thrombocytes
Aggregation tests under TEM revealed the following abnormalities: 
1) Lack of adhesion: At the 2nd, 8th, and 14th minutes of the 
aggregation test, the thrombocytes were still separate from 
each other. At the second minute, the granules were fairly or 
completely centralized with no visible pseudopods, whereas 
normal thrombocytes fit together tightly, displayed abundant 
blunt pseudopods, and had released almost all of their granules 
(Case 1, Case 2, and control). 2) Lack of or inadequate secretion: 
Organelle centralization took place but the organelles later became 
dispersed in the cytoplasm, without undergoing secretion and with 
Supplemental Figure 1. The platelet dense granules stained by 
mepacrine (arrow).
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Supplemental Table 1. Primers used for the 
sequencing of the coding regions of HAX1, ELANE, 
G6PC3, CSF3R, JAGN1 genes.
HAX1-1F ACTGGAGGGGTTCAAAGGTT 
HAX1-1R ATCACCCC AGGTTGGAGAA 
HAX1-2F TCC CACTTTGCCACCCATGAGT
HAX1-2R TTCTCACACTTCCCATCCCC
HAX1-3F CCTTTCCCATCCCAGCAAACACC
HAX1-3R CT CACAAGCTCTCACTTCAGGACCA
HAX1-4F G GGGTTTTGGAGCTCGGGAGTAGTT
HAX1-4R TTCAGGGAGGGAGAACACACAG A
HAX1-5,6F CTCCTGCTTCTTCATCTCTC TGCTC
HAX1-5,6R AGGCAGAAGCAAAGGACAAGGG
HAX1-7F CTCAAGATTCCTTGGGGAAG
HAX1-7R CGGAAGTGTTGGAT GGTTCT
ELANE-2,3F CGGAGGGGCAGAGACCCCGGA
ELANE-2,3R AGACCGGGACGCGGGGTCCGA
ELANE-4F CTCGAGCACCTTCGCCCTCAG
ELANE-4R TCAACGGCCCATGGCGGGTAT
ELANE-5-6F CCTGCCCTGCAGGATCCCAGA 
ELANE-5-6R GGAGAGTGTGGGTGTGGGCAG
CSF3R-3R AAGGAAATTCCCAATATCTCTCC 
CSF3R-4F CCAGGGTCTGCTTTTCTCTG 
CSF3R-4R AGGCACCCGCCACTATG 
CSF3R-5-6F AGGAAGCTTTCTGAGTGGTCC 
CSF3R-5-6R TGTGTTTCCCTCTCCATTCC 
CSF3R-7-8F AGAGCCCTCTAGGGTGGG 
CSF3R-7-8R GGGGCCTGGACTGGATAC 
CSF3R-9F GTATCCAGTCCAGGCCCC 
CSF3R-9R CTAAGCCCCGGTTTGTAGG 
CSF3R-10F CCTAGAGGCTCTCCTTGACTC 
CSF3R-10R CCAGGCAGTCTAGCCTTTG 
CSF3R-11F CAGGCTTCTGGCTCAAGG 
CSF3R-11R TCAGATAAGCACTGCCTCCC 
CSF3R-12F GCTCCTGATCATTAGCACAGG 
CSF3R-12R AGAGCCTTGGGAGAGAGAGG 
CSF3R-13-14F AGAAGTCCAACCGGGCTC 
CSF3R-13-14R AAATCAGCATCCTTTGGGTG 
CSF3R-15-16F AGACCCAGCCTTCCCAAC 
CSF3R-15-16R CTTGGCTTCAGAAGGTGTCC 
CSF3R-17F CCAGACAGGGACAGTGGC 
CSF3R-17R ACCCTCCCCTCTTCTCCAG 
G6PC3-1F GTGATAGCCGAGGCGCTACAG
G6PC3-1R AGGGCTTACACATGACTCAGGG
G6PC3-2F GAGTACTCTGTGTCCTGCCCG
G6PC3-2R CTCTGAAATGTTCACCCGAACC
G6PC3-3F CAGCTGTATTATTGAGGCATCACC
G6PC3-3R GCCATGCTGCTGTGTCTATTAGG
G6PC3-4F TTCAACCATGGAGTACCTGGG
G6PC3-4R GTGGGCTCTACAGAAGCTGGG
G6PC3-5F ATTCTCTTGCCAAGCTGCACTG
G6PC3-5R AGGCTAGGTGCAGGCGAGATAG
G6PC3-6aF GATAGCCTGCCTTGTGCTGG
G6PC3-6aR CGGAAGCAGATTTAGGGAGGG
G6PC3-6bF CAGTGGCCTTCTATGTTCCAGC
G6PC3-6bR GGCCAGAGGGTGTACTTGAGG
JAGN1_1F GTGTCGTTGCGGTACCAGG
JAGN1_1R GGGGAGCAAGACCCTGAG
JAGN1_2F TTGTCTGGCATATAGTTGGTGG
JAGN1_2R AAGGGATTTTGGAACCGC
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unevacuated large granules and no enlargement in the OCS (Case 2) or having made 
partial secretion with enlarged OCS full of unsecreted material (Cases 1 and 2). 
3) Delay in all stages of aggregation: Each stage of aggregation (centralization, 
development of pseudopods, and/or absent or impartial secretion) took place with 
delay (Case 1, Case 2, and control). 4) Abnormal degranulation: Unlike in normal 
degranulation, in which the dissolution of the granule’s membrane is followed 
by evacuation of granule contents into the OCS and canalicular dilation, in some 
samples of the patients the dense granule was evident in the OCS, without membrane 
dissolution (Case 1). 5) Dissociation phenomenon: The patients’ platelets showed 
the dissociation phenomenon, a disruption of normal aggregation that normally 
takes place in a coordinated sequence of pseudopod formation, change in shape, 
clustering of central granules, degranulation, and canalicular dilation [8,9]. In our 
cases, all of these changes took place without the adherence of thrombocytes to 
each other. We observed OCS enlargement and secretion of some material taking 
place before the degranulation phase ended (Case 1). 6) Abnormal cytoplasmic 
protrusions: The cytoplasmic protrusions in normal aggregating thrombocytes were 
thin, whereas in our patients they were amoeboid (Cases 1 and 2). 
Clinical Correlations Between Hemorrhagic Diathesis and Laboratory Parameters 
It was striking that not all cases with a history of hemorrhagic diathesis displayed 
abnormal aggregation test results, low dense granule number in thrombocytes, 
or prolonged in vitro bleeding time, whereas many cases without any history 
of hemorrhagic diathesis displayed abnormal aggregation test results or low 
dense granule number in thrombocytes or prolonged bleeding time or abnormal 
ultrastructure of thrombocytes. Not all of these abnormalities coexisted all together 
(Table 2; Supplemental Table 5). 
Supplemental Discussion
Text 1
In the steady state apoptotic cells are rarely encountered under physiological 
conditions and the removal of the apoptotic cells is fast and promotes an 
anti-inflammatory response [10]. However, in the case of substantial and excessive 
apoptosis during which the capacity of phagocytes to engulf apoptotic cells is 
reduced, the uncleared apoptotic cells and fragments undergo secondary necrosis 
(delayed apoptotic clearance) which can provoke inflammation or autoimmunity. 
Macrophages that ingest necrotic cells cause increased T cell proliferation [10]. 
Hence, the flow cytometric graphics show that apoptotic and necrotic cells coexisted 
in all three cell lines, confirming that necrosis was due to excessive apoptosis. Hence, 
phagocytosis of both necrotic and apoptotic cells were shown in the bone marrow 
of the patients.
However, presence of excessive apoptosis and secondary necrosis not only in 
the patients’ neutrophils but in all other cell lines (lymphocytic and monocytic) 
regardless of the mutation type of congenital neutropenia and their existence 
even in the non-neutropenic parents of the congenital neutropenia patients seem 
unreliable at first glance. 
We think that macrophages of our patients were activated by increased apoptosis in 
the myeloid lineage, and the TNF-alpha secreted by activated macrophages gave rise 
to increased apoptosis (and secondary necrosis) in all cell lineages. Hence, striking 
phagocytic activity of various phagocytic cells (histiocytes, monocytes, macrophages, 
neutrophils, bands and even eosinophils and eosinophil myelocytes), mainly being 
monocytic cells, and our previous findings showing elevated TNF-alpha which is 
mainly secreted by activated macrophages in a group of congenital neutropenia 
patients, most of whom also enrolled in this study [11], confirm our explanation. 
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Supplemental Table 2. Characteristics of the parents.
Age Symptoms / findings Molecular genetics Leukocyte 
count  
(WBC; x109/L)
(n=4.0-10.0)
Neutrophil 
count  
(109/L, %)
(n=1.9-8.0)
Monocyte 
count  
(x109/L, %)
(n=0.12-1.2)
Lymphocyte 
count  
(x109/L, %)
(n=0.9-5.2)
Thrombocyte 
count  
(x109/L, %)
(n=130-400)
Father of MK 38y - NA† 7.0 3.6 0.8 2.5 365
Mother of MNY-
AY siblings*
34y - HAX1 heterozygousc.130-
131insA (p.W44X)**
8.3 5.2 0.5 2.5 312
Father of MNY-
AY siblings*
37y - HAX1 heterozygous 
c.130-131insA (p.W44X)**
8.48 5.77 0.62 1.8 304
Mother of MeK-
OSK siblings
55y - NA† 9.24 4.38 0.77 3.91 314
Father of MeK-
OSK siblings
54y - NA† 8.7 5.6 0.8 2.1 322
Mother of AF* 28y Gingival enlargement NA† 8.8 5.4 0.8 2.3 247
Father of AF 32y Frequent aphthae NA† 8.9 5.6 0.7 2.3 211
Mother of EÇ* 26y Gingival enlargement 
gingival bleeding
HAX1 heterozygous 
c.130-131insA (p.W44X)**
6.82 4.26 0.61 1.80 241
Father of EÇ* 25y - NA* 8.32 5.37 0.57 2.07 238
Mother of HY* 29y - HAX1 heterozygous 
c.130-131insA (p.W44X)**
7.38 4.75 0.52 1.94 268
Father of HY* 32y - HAX1 heterozygous 
c.130-131insA (p.W44X)**
10.15 5.87 0.70 3.18 287
Mother of RT* 30y - No ELANE*** 10.0 7.3 0.3 2.3 261
Father of RT* 34y - No ELANE*** 14.1 11.3 0.6 2.1 280
Mother of NBÖ* 46y Easy bruising No ELANE*** 4.7 2.8 0.3 1.6 242
Father of NBÖ* 49y - No ELANE*** 5.1 2.3 0.5 2.1 251
Mother of AO 29 Easy bruising NA† 7.9 5.2 0.4 2.2 361
Father of AO 36y Gingival enlargement NA† 8.0 4.8 0.48 2.4 328
Mother of BA 32y - NA† 6.4 4.0 0.4 1.9 366
Father of BA 38y Easy bruising NA† 9.4 6.3 0.6 2.2 248
Mother of AG-
ZG siblings*
23y - NA† 6.7 3.6 0.56 2.24 205
Father of AG-ZG 
siblings*
27y Easy bruising NA† 6.84 3.88 0.57 2.12 227
*Those who could be evaluated for death parameters by flow cytometry, **Peripheral blood cells, ***Peripheral blood cells  and buccal mucosa cells, †NA: Not available.
Supplemental Table 3. The number and percentage of the patients and their parents whose lymphocyte subset levels were below 
and above age matched normal range.
CD3 CD4 CD8 CD4/CD8 NK
Below 
normal 
Above 
normal 
Below 
normal 
Above 
normal 
Below 
normal 
Above 
normal 
Below 
normal 
Above 
normal 
Below 
normal 
Above 
normal 
Patients (n=11)
2 2 1 0 0 3 0 0 4 0 
16.6% 16.6% 8.3% 0% 0% 27.3% 0% 0% 36.4% 0%
Parents (n=13)
0 0 0 0 0 1 0 0 2 0
0% 0% 0% 0% 0% 7.7% 0% 0% 15.4% 0%
Control (n=18)
0 0 0 0 0 3 0 0 1 0
0% 0% 0% 0% 0% 16.7% 0% 0% 5.6% 0%
Supplemental Table 4. In vitro bleeding time of the cases.
Collagen-epinephrin (n=85-157 sn) / (No of cases) Collagen-ADP (n=65-125 sn) / (No of cases)
Patients 150.25+28.89 (n=8) 121.0±22.5 (n=6)
Parents 131.9±35.5 (n=16) 110.3±74.1 (n=8)
Control 129.2+28.8 (n=9) 88.3±12.2
P (Patients-parents) 0.293 0.233
P (Patients-control) 0.293 0.031
P (Parents-control) 0.293 1.000
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Additionally, studies of other colleagues showing enhanced stimulating effect 
of monocyte activation through toll-like receptors on TNF-alpha production 
[12,13], and increased baseline cytokines including TNF-alpha in children with 
congenital neutropenia [14] also draw attention to the role of TNF-alpha and 
other inflammatory cytokines in congenital neutropenia. 
Monocytes are activated by microbial products as well as molecules expressed or 
released by dying or stressed cells through toll-like receptors, interferon gamma, 
Th1 cells or complement fragments [15]; additionally removal mechanisms of 
necrotic and apoptotic cells may overlap [10]. Once activated, macrophages 
secrete TNF-alpha, IL-1, IL-6 and IL-12, the latter of which is also secreted 
by dendritic cells and stimulates IFN-gamma production by NK and T cells 
thereby exacerbating macrophage activation [15,16]. Hence, elevations of pro-
inflammatory cytokines in congenital neutropenia were reported before [11,14]. 
TNF-alpha which is mainly secreted by macrophages is a well known 
cytokine to give rise to apoptosis in neutrophils [17,18], lymphocytes [19,20], 
monocytes [21], and thrombocytes [22] in various conditions like sepsis, HLH 
[23], stroke, and ankylosing spondilitis and secreted mainly by macrophages 
and through TNF alpha and TNFR1 interaction.
Therefore, the factor that stimulates macrophage activation in our 
patients, none of whom had any major infection other than gingivitis 
or aphthous stomatitis at the time of evaluation, seems to be excessive 
apoptosis (thereby secondary necrosis) in the granulocytic lineage due 
to various mutations distrupting normal granulopoiesis. Apoptosis and 
secondary necrosis of other cell lines like lymphocytes and monocytes 
as shown by flow cytometry, and in megakaryocytes as shown by light 
microscopy are thought to be secondary to increased TNF-alpha through 
excessive macrophage activation. 
Text 2
On the other hand, RCS in 25% and 12.5% of the evaluated patients and 
parents, documented by β-gal positivity of leukocytes may be another reason for 
quantitative abnormalities in T lymphocytes. That the patients with low CD3+ 
and CD4+ lymphocytes (sibling patients AG, ZG) were those with β-gal positivity 
of leukocytes showing RCS and with normal NK levels suggests a relationship 
between T-lymphopenia and RCS. Presence of immune activation in our patients 
documented by increased phagocytic activity in their bone marrow suggests 
that continual presence of circulating pro-inflammatory aforementioned factors 
secreted by activated macrophages had kept the immune system in a state of 
chronic low-level activation giving rise to an immunosenescence through loss 
of telomeric DNA with each S phase, and therefore a decline in the absolute 
number of T and B lymphocytes, with no change in overall lymphocyte count 
but a relative increase in NK cells [24] (in our patients we could not evaluate B 
lymphocytes). A set of mediators including inflammatory mediators secreted by 
senescent cells themselves contribute to the chronic inflammation [25] and the 
loss of telomeres. Likewise, a previous study of ours showed RCS (β-gal positivity) 
of leukocytes in active autoimmune disorders [systemic lupus erythematasus 
(SLE), juvenile rhematoid arthritis (JRA), and immune thrombocytopenic purpura 
(ITP)], in all of which pro-inflammatory cytokines are high [26].
Text 3
Dysmegakaryopoiesis and Hemorrhagic Diathesis
In our patients one of the most prominent findings was abnormal 
megakaryopoiesis evidenced by naked megakaryocyte nuclei (NMN), S
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Supplemental Table 6. Laboratory parameters of the parents.
Family of the patient 
that is examined/
mutation of the 
patient
Parent/molecular genetics Lymphocyte 
subsets in 
comparison to 
age matched 
normal ranges
Dense granule per 
thrombocyte 
(n=2.78-3.82)/
Bleeding time (in vitro) 
(Coll-epi* n=85-157 s; 
Coll-ADP** n= 65-125 s)
Aggregation defect
Family of YF/ 
HAX1 homozygous 
c.130-131insA (p.W44X)
Mother/NA† NK:25-50p 
CD3:25-50p 
CD4:<25p 
CD8:25-50p 
CD4/CD8:25-50p
3.2/coll-epi: 120 s No secondary aggregation with 2 and 6 µM 
ADP; hypoaggregation with epinephrin (10 
µM/mL), normal aggregation with collagen 
(1µg/mL) and ristocetin (1.25 mg/mL)
Father/NA† ND 2.1/coll-epi: 152 s No secondary aggregation with 2 and 6 µM 
ADP; normal aggregation with epinephrin (10 
µM/mL), collagen (1µg/mL), and ristocetin (1.25 
mg/mL)
Family of MNY/AY 
Both HAX1/ 
Homozygous c.130-
131insA (p.W44X)
Mother 
HAX1 heterozygous  c.130-
131insA (p.W44X)***
NK<25p;CD3>75p 
CD4:25-50p 
CD8>75p 
CD4/CD8<25p
4/coll-epi: 154 s ND
Father 
HAX1 heterozygous  c.130-
131insA (p.W44X)***
NK<25p 
CD3:50-75p 
CD4>75p 
CD8<25p 
CD4/CD8>75p
0.23/coll-epi:122 s Secondary aggregation defect and 
and disaggregation with ADP (10 µM), 
hypoaggregation with collagen (2 μg/mL), 
normal aggregation with ristocetin  
(1.25 μg/mL) (epinephrin not available)
Family of MK/ 
HAX1 homozygous 
c.130-131insA (p.W44X)
Father/NA† ND ND/ND Hypoaggregation with ADP (10 µM) and 
collagen (1 µg/mL), normal aggregation with 
ristocetin (1.25 μg/mL)
Family of EÇ/ 
HAX1 homozygous 
c.130-131insA (p.W44X)
Mother 
HAX1 heterozygous  c.130-
131insA***
NK<25p 
CD3>75p 
CD4:50-75p 
CD8:50-75p 
CD4/CD8:50p
3.6/coll-epi:134 s;
Coll-ADP:103 s
Normal aggregation with ADP (10 µM), 
collagen (2 µg/mL), ristocetin (1.25 mg/mL)
Father NA* NK<25p 
CD3:25-50p 
CD4>75p 
CD8<25p 
CD4/CD8>75p
3.5/coll-epi:151; coll-
ADP:80 s
Normal aggregation with ADP (10 µM), 
collagen (2 µg/mL), ristocetin  
(1.25 mg/mL)
Family of HY/ 
HAX1 homozygous 
c.130-131insA (p.W44X)
Mother
HAX1 heterozygous  c.130-
131insA (p.W44X)***
NK<25p 
CD3>75p 
CD4:25-50p 
CD8:25-50p 
CD4/CD8:50p
4.5/coll-epi:76 s;
Coll-ADP:48 s
Secondary aggregation defect and 
disaggregation with ADP (10 µM), normal 
aggregation with collagen (2 µg/mL), ristocetin 
(1.25 mg/mL)
Father
HAX1 heterozygous  c.130-
131insA (p.W44X)***
NK:25-50p 
CD3:50-75p 
CD4:25-50p 
CD8:25-50p 
CD4/CD8:50p
0.9/coll-epi: 166 s; coll-ADP: 
115 s
Secondary aggregation defect and 
disaggregation with ADP (10 µM),  
collagen (2 µg/mL), ristocetin  
(1.25 mg/mL)
Family of OSK/MeK 
G6PC3 homozygous, 
c.194A>C (p.E65A)
Father/NA† ND 2.3/ND Normal aggregation with ADP (2 µM), 
hypoaggregation with epinephrin (10 µM/mL), 
collagen (1µg/mL) and ristocetin (1.25 mg/mL)
Family of the patient 
that is examined/ 
mutation of the patient
Parent/molecular genetics Lymphocyte 
subsets in 
comparison to 
age matched 
normal ranges
Dense granule per 
thrombocyte 
(n=2.78-3.82)/
Bleeding time (in vitro) 
(Coll-epi* n=85-157 s; Coll-
ADP** n=65-125 s)
Aggregation defect
Family of RT/
ELANE 
Heterozygous 
IVS4+5G>A
Mother
No ELANE mutation****
NK<25p 
CD3:50-75p 
CD4>75p 
CD8<25p 
CD4/CD8>75p
3.95/coll-epi: 142 s; coll-
ADP: 96 s
Normal aggregation with ADP  
(2 and 6 µM), epinephrin (10 µM),  
collagen (1 µg/mL), ristocetin (1.25 mg/mL)
Father
No ELANE mutation****
NK<25p 
CD3>75p 
CD4:25-50p 
CD8:50-75p 
CD4/CD8:25-50p
3.26/coll-epi: 107 s; coll-
ADP:65 s
Normal aggregation with ADP  
(2 and 6 µM), epinephrin (10 µM),  
collagen (1 µg/mL), ristocetin (1.25 mg/mL)
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megakaryocyte emperipolesis, megakaryocytes with features 
of apoptosis, paraapoptosis, necrosis, and abnormalities in 
thrombocyte aggregation.
Naked megakaryocyte nuclei form after progressive folding of 
lobulated nucleus itself and then contracting (pyknosis), in order to 
reach the lowest volume that the megakaryocyte can occupy. The 
surrounding small rim of cytoplasm contains no characteristic MK 
granules or demarcation membranes. In physiological conditions, 
NMN are senescent cells which completed thrombocyte shedding and 
are few in normal bone marrow. However, large numbers of NMN in 
the bone marrow, like in myeloproliferative diseases and AIDS show 
defective maturation, a heavy intramedullary premature cell death 
of megakaryocytes and increased megakaryopoies [27, 28].
Emperipolesis [29,30] is a random passage of one cell through 
the cytoplasm of another one with no physiological change in 
neither of them. It is most frequent in megakaryocytes and the 
most engulfed cell types are neutrophils and erythrocytes, as in our 
patients. 
Naked megakaryocyte nuclei [27] and megakaryocytes with 
emperipolesis [29] were shown to display the features of 
paraapoptosis (non classical apoptosis). 
While apoptosis is characterized by margination of condensed 
chromatin, nuclear fragmentation and formation of apoptotic 
bodies, paraapoptosis of megakaryocytes is characterized by 
cytoplasmic vacuolization due to mitochondrial swelling and 
distended demarcation membrane system (DMS), condensed 
nuclear chromatin with no early chromatin margination and no 
surface blebbing and apoptotic body formation. All paraapoptotic 
megakaryocytes were shown to have an intact, thickened peripheral 
zone which seemed to contain no functional cellular material, like 
organelles or DMS and their cytoplasm did not contain thrombocyte 
territories [31], like in our patients. 
Additionally presence of many stage 1 megakaryocytes 
(megakaryoblasts), some of which are aberrantly releasing 
thrombocytes, unlike what is expected, also show 
dysmegakaryopoiesis [32]. 
That presence of nearly no normal megakaryocytes in our patients 
and that nearly all megakaryocytes displayed characteristics of NMN, 
emperipolesis or abnormal morphology like peripheral vacuolization 
(showing non-classical apoptosis: paraapoptosis and directly 
destructed megakaryocytes (showing necrosis) imply defective 
megakaryocyte maturation, a heavy intramedullary premature cell 
death of megakaryocytes and increased megakaryopoiesis.
Defective maturation in megakaryocytes is also expected to be 
due to the increased levels of aforementioned proinflammatory 
cytokines secreted by and after macrophage activation which can 
destroy the bone marrow microenvironment and hematopoietic 
stem cell niches [25] giving rise to hematopoietic stem cell 
dysfunction and dyshematopoiesis and thereby generalized 
Supplemental Table 6. Continued.
Family of the patient 
that is examined/
mutation of the patient
Parent/molecular genetics Lymphocyte 
subsets in 
comparison to 
age matched 
normal ranges
Dense granule per 
thrombocyte 
(n=2.78-3.82)/
Bleeding time (in 
vitro) (Coll-epi* 
n=85-157 s; Coll-
ADP** n=65-125 s)
Aggregation defect
Family of BA  
Unidentified mutation
Father//NA† NK<25p 
CD3:50-75p 
CD4>75p 
CD8<25p 
CD4/CD8>75p
3.5/coll-epi: 97 s No secondary aggregation with 2µM ADP and 
epinephrin (10 µM/mL) but normal aggregation with 6 
µM ADP, collagen (1µg/mL), and ristocetin (1.25 μg/mL)
Family of AG/ZG
Unidentified mutation
Mother//NA† NK<25p 
CD3:50-75p 
CD4>75p 
CD8<25p 
CD4/CD8>75p
0.76/coll-epi: 134s Normal aggregation with ADP  
(2 and 10 µM), collagen (2 µg/mL), ristocetin  
(1.25 mg/mL)
Father//NA† NK<25p 
CD3>75p 
CD4>75p 
CD8<25p 
CD4/CD8>75p
0.98/ coll-epi: 193 s; 
coll-ADP>300 s
Normal aggregation with ADP (10 µM), collagen (2 µg/
mL), ristocetin (1.25 mg/mL)
Family of NBÖ/ 
Heterozygous  
ELANE c.416C>T
Mother
No ELANE mutation***
ND 1.8/coll-epi: 82 s Normal aggregation with ADP  
(2 and 6 µM), epinephrin (10 µM),  
collagen (1 µg/mL), ristocetin (1.25 mg/mL)
Father
No ELANE mutation*** ND
2.0/coll-epi: 91 s No secondary aggregation with ADP (2 µM) but normal 
aggregation with ADP (6 µM), epinephrin (10 µM), 
collagen (1 µg/mL), ristocetin (1.25 mg/mL)
Family of AO  
Unidentified mutation
Mother/NA† ND 0.22/coll-epi: 189 s; 
coll-ADP:103 s
Normal aggregation with ADP (2 and 6 µM), collagen 
(1 µg/mL), ristocetin (1.25 mg/mL). Prolonged lag phase 
with epinephrin (10 µM)
*Collagen-epinephrin cartridge, **Collagen-ADP cartridge, ***Peripheral blood cells, ****Peripheral blood cells and buccal mucosa cells, †NA: not available.
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dysplastic findings of bone marrow cells, as it is for the other bone 
marrow cells. 
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